In 2012, vaccines containing cell-cultured virus became available. Even though eggs continued to be the primary means of production, cell culture emerged as an alternative method for producing influenza vaccines.

Originally, this production process also began with chicken egg-grown CVVs per U.S. Food and Drug Administration regulations. However, on August 31, 2016, the  FDA issued an approval for Seqirus, the sole FDA-approved cell culture-based flu vaccine manufacturer in the United States, to begin using cell culture-grown CVVs. Currently, cell culture-based manufacturing is used to make inactivated flu vaccines (i.e., flu shots).